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Wenwen Fang1, Yong Wei1, Yibin Kang1 and Laura F Landweber2*Abstract: Interchromosomal chimeric RNA molecules are often transcription products from genomic rearrangement
in cancerous cells. Here we report the computational detection of an interchromosomal RNA fusion between
ZC3HAV1L and CHMP1A from RNA-seq data of normal human mammary epithelial cells, and experimental
confirmation of the chimeric transcript in multiple human cells and tissues. Our experimental characterization also
detected three variants of the ZC3HAV1L-CHMP1A chimeric RNA, suggesting that these genes are involved in
complex splicing. The fusion sequence at the novel exon-exon boundary, and the absence of corresponding DNA
rearrangement suggest that this chimeric RNA is likely produced by trans-splicing in human cells.
Reviewers: This article was reviewed by Rory Johnson (nominated by Fyodor Kondrashov); Gal Avital and Itai Yanai
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High-throughput sequencing techniques have allowed
characterization of genome and transcriptome catalogs
in an unprecedented detail, revealing complex structures
of genome rearrangements [1] and transcript networks
of chimeric RNAs in human cells [2]. Because genome
instability is a hallmark of cancer [3], most studies of
genome rearrangements and RNA fusions focus on can-
cer cells, and some chimeric RNAs appear to result from
DNA rearrangements [4-8]. In fact, some studies use
RNA-seq data as a guide to annotate genome rearrange-
ment [9]. Several findings, however, suggest that normal
human cells also produce chimeric RNA through trans-
splicing [10-13]. Notably, Li et al. demonstrated that in
normal endometrial cells, trans-splicing produces a
chimeric RNA that is identical to a fusion transcript
present in endometrial stromal tumor cells [13]. The
corresponding chromosomal translocation which may
permit production of this chimeric RNA by cis-splicing
is present in endometrial tumor cells, but not detectable
in normal endometrial cells. This hints at the possibility
that RNA fusion may even predispose relevant genomic
loci to rearrangement [13,14], via RNA-guided DNA
recombination, which our lab previously discovered in
the ciliate Oxytricha [15].* Correspondence: lfl@princeton.edu
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reproduction in any medium, provided the orWe therefore asked whether we can identify more
occurrences of chimeric transcripts, especially those
involving genes on separate chromosomes, in normal
human cells. We mined high-throughput RNA-seq data
from human mammary epithelial cells (HMEC) available
from the ENCODE project [16]. The deFuse program
[17] predicted one interchromosomal RNA fusion
between the genes encoding ZC3HAV1L (zinc finger
CCCH-type, antiviral 1-like) and CHMP1A (charged mul-
tivesicular body protein 1A), located on chromosomes 7
and 16, respectively (Figure 1A). ZC3HAV1L contains 5
exons and encodes a 300 residue protein. CHMP1A has
two protein-coding transcript isoforms, according to
NCBI annotation; transcript variant 1 contains 6 exons
encoding a 240 residue protein, and transcript variant 2
contains 7 exons encoding a 196 residue protein, which
functions as a tumor suppressor in human kidney and
pancreas [18,19]. CHMP1A isoform 1 skips exon 2, but
has a larger exon 7. Here we used CHMP1A isoform 1 as
the reference for annotation purposes, because the fusion
product we detect contains the larger exon 7 (see below).
Because we initially predicted the presence of the
ZC3HAV1L-CHMP1A fusion in a breast cell line, we first
verified the presence of this chimeric transcript in
human mammary cells. Use of a primer pair (Table 1)
that amplifies across the predicted ZC3HAV1L-CHMP1A
fusion junction (from ZC3HAV1L exon 2 to CHMP1A
exon 6) confirms the presence of this fusion at the RNAd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Detection of ZC3HAV1L-CHMP1A chimeric RNA in human cells. (A) Schematic representation of the ZC3HAV1L-CHMP1A chimeric
RNA. Blue and yellow boxes indicate exons from ZC3HAV1L and CHMP1A, respectively. Above the predicted fusion, colored bars indicate paired
reads from the ENCODE HMEC RNA-seq data. The same color indicates a read pair supporting the fusion. Arrows below the predicted fusion
indicate primer pairs used in PCR analyses (primer pair a for PCR in panel B, and primer pairs b and c for nested PCR in panel E). (B) RT-PCR
detection of the ZC3HAV1L-CHMP1A chimeric RNA in human cells and tissues. Filled arrowhead indicates the major predicted fusion; open
arrowheads indicate minor alternative chimeric transcripts (i-iv). “RT -” indicates no reverse transcriptase negative controls. “NTC” indicates no
template control for PCR analysis. (C) Junction sequence of the ZC3HAV1L-CHMP1A chimeric RNA. Blue and yellow shading highlights sequences
from the end of ZC3HAV1L exon 4 and start of CHMP1A exon 5, respectively. Lower case letters indicate intron sequences. The chromatogram
shows Sanger sequencing results at the junction from RT-PCR analysis of HMLE cells. (D) Schematic representation of minor alternative
ZC3HAV1L-CHMP1A chimeric RNAs detected from PCR shown in (B). Partial exon and introns (“i”) are indicated by different shades of color.
Sequence alignment for the major and minor chimeric RNAs is provided in an additional file. (E) ZC3HAV1L-CHMP1A fusion may encode a novel
protein. Shown is nested RT-PCR amplification of the predicted fusion coding sequence from HMLE and CAPAN1 cells. The larger band indicates
the expected PCR product, whereas the smaller band in HMLE lane indicates the ZC3HAV1L exon3- variant. (F) ZC3HAV1L-CHMP1A chimeric RNA
levels differ in different human cell and tissue types. The copy number of the RNA fusion between ZC3HAV1L exon 4 and CHMP1A exon 5 is
normalized against beta-actin mRNA.
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derived from HMEC, but not at the DNA level from
matching genomic DNA (Figure 1B). Sequencing of the
PCR product verified the fusion junction (Figure 1C). The
same PCR analysis suggests that the ZC3HAV1L-CHMP1A
fusion is present in MCF10A, an immortalized but other-
wise normal human mammary epithelial cell line, as well as
two human breast cancer cell lines, MB-MDA231 and
MCF7. We also detected the fusion in CAPAN1, a pan-
creatic cancer cell line, human embryonic kidney (HEK)
293 T cells, and CEMT, a human T cell line. In addition, we
were able to amplify the fusion RNA from commercially-
available human universal reference RNA and a panel of
human tissue RNAs (Figure 1B). These results suggest that
the ZC3HAV1L-CHMP1A chimeric RNA is common
across multiple human tissue types, both healthy and
diseased.
Curiously, we detected some minor PCR products of dif-
ferent sizes as well. Sequencing revealed that some of them
reflect alternative splicing of the ZC3HAV1L-CHMP1A
chimeric RNA, adding additional complexity to this fusion
transcript. A common splicing variant present in multiple
tissue types is the full-length chimeric RNA skipping
ZC3HAV1L exon 3 (Figure 1B, D). Two other minor
RT-PCR products suggest splicing between partial intron
2 and exon 3, and partial exon 3 and intron 3 of
ZC3HAV1L, respectively (Figure 1B, D). Sequence align-
ments (see Additional file 1) indicate that these alterna-
tive splicing events all occur at canonical splicing sites,
suggesting that they likely derive from authentic, alterna-
tive RNA splicing, rather than an in vitro RT-PCR
artifact. A fusion product detected from RT-PCR analysis
of human prostate RNA fuses ZC3HAV1L exon 4 to part
of CHMP1A exon 6, not at canonical splicing site but
between a pair of 5 bp direct repeats at the boundary.
Therefore, this may represent either an endogenous acti-
vity or just template-switching during the reverse tran-
scription step in our experimental procedure.
The major chimeric, fusion RNA that joins exon 4 of
ZC3HAV1L to exon 5 of CHMP1A preserves the openreading frame. We therefore tested whether the entire
open reading frame could be detected from mRNA by
nested PCR. The use of primers located upstream and
downstream of the predicted start and stop codons in
the first round of PCR, and then a nested primer pair
between the start and stop codons did amplify a product
containing the predicted open reading frame, as well as
the ZC3HAV1L exon3- version of the transcript, though
at much lower levels, consistent with our previous PCR
result (Figure 1E). We infer that the major chimeric
RNA that joins ZC3HAV1L and CHMP1A may encode a
novel fusion protein. Predicted domains are not available
for either fusion partner, however, precluding further
structural and functional predictions of this putative
fusion protein.
From qPCR analysis, we estimated that the ZC3HAV1L-
CHMP1A chimeric RNA is present at ~ 0.1 copies per
HMLE cell, suggesting that its expression is limited to
either a small population of cells, or a transient time
window. We also assayed the relative abundance of this
chimeric RNA compared to beta-actin, a constitutively
expressed gene, and found that the relative levels of the
ZC3HAV1L-CHMP1A chimeric RNA differ in different
samples (Figure 1F). This suggests that the production of
ZC3HAV1L-CHMP1A RNA might be regulated, or it
might be a stochastic event.
In summary, we report the discovery of a chimeric
RNA between ZC3HAV1L and CHMP1A in human,
located on chromosome 7 and 16, respectively. The fu-
sion occurs at an exon-exon boundary, and was detected
both computationally and experimentally from different
cells or tissue types. This suggests it is not an artifact
from reverse transcription, and is likely an authentic
trans-splicing product. We also detected three minor
variants which also likely result from trans-splicing,
because the fusion occurs at canonical “GT-AG” splicing
sites. The fusion products are present at very low levels,
and thus may reflect promiscuous splicing involving
ZC3HAV1L and CHMP1A.
Could such low abundance chimeric RNAs have any
function? While the major chimeric RNA that we
detected preserves open reading frame and could po-
tentially produce a novel fusion protein or proteins, we
propose that such examples of chimeric RNA may also
occasionally impact somatic genome rearrangements,
facilitating rogue recombination events between the
two respective chromosomes [14,15]. The ability of
RNA to influence genome remodeling has gained con-
siderable support and interest over the past few years
[20], but RNA-guided DNA rearrangement in humans
still needs further investigation, emphasizing the im-
portance of detecting more chimeric RNAs and their
possible DNA rearrangements in normal or diseased
tissue.
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Computational detection of fusion RNAs
HMEC polyA-RNA-seq data from ENCODE project
(http://hgdownload.cse.ucsc.edu/goldenPath/hg19/enco-
deDCC/wgEncodeCshlLongRnaSeq/) were downloaded
from UCSC genome browser website. DeFuse 0.4.3 [17]
was used to detect fusion transcripts, requiring the pre-
sence of two pairs of spanning reads and one split read
at the junction. We divided the RNA-seq data into subsets
of 10 and 20 million paired-end reads to accommodate
computation memory, and the ZC3HAV1L-CHMP1A
fusion was predicted in two independent subsets of data.
RNA and genomic DNA extraction
Total RNA from HMLE, MB-MDA231, MCF7, CAPAN1,
MCF10A, HEK293T, and CEMT cells was extracted using
RNeasy (Qiagen), and DNase treated with TURBO DNA-
free kit (Ambion) following the manufacturer’s instructions.
Human reference RNA was purchased from Stratagene,
and the human tissue RNA panel was purchased from
Clontech. Genomic DNA was extracted using NucleoSpin
Tissue (Macherey-Nagel).
cDNA synthesis
3.5 μg of RNA was reverse transcribed with SuperScriptIII
reverse transcriptase (Invitrogen), in a 20 μl reaction follo-
wing the oligo(dT) priming protocol.
PCR analysis
FastStart High Fidelity PCR system (Roche) was used to
amplify fusion product from 1μl of cDNA (equivalent of
175 ng RNA), or 200 ng genomic DNA. To detect the
predicted fusion from ZC3HAV1L exon 2 to CHMP1A
exon 6, the following program was used: 95°C 2 min
initial denaturing; 95°C 30 s, 58°C 30 s, 72°C 45 s for
36 cycles; 72°C 7 min. To recover the entire coding
region by nested PCR, the following program was used.
First round: 95°C 2 min initial denaturing; 95°C 30 s,
60°C 30 s, 72°C 90 s for 20 cycles; 72°C 7 min. The PCR
reaction was diluted 100 fold, and used in the second
round of PCR: 95°C 2 min initial denaturing; 64°C 30 s,
72°C 80 s for 30 cycles; 72°C 7 min.
Sanger sequencing of PCR products
PCR products were either sent for direct Sanger sequen-
cing (Genewiz) following Genewiz DNA sequencing
instructions, or TOPO-cloned (Invitrogen) for colony
PCR and sequencing (Genewiz).
qPCR analysis
The 7900HT Fast Real-Time PCR System and SYBR
green master mix (Applied Biosystems) were used for
qPCR analysis with the default cycling program. Stan-
dard curves for each primer pair were generated withfive ten-fold serial dilutions of appropriate control plas-
mids in yeast RNA, allowing absolute quantification of
DNA levels. Primer specificity was confirmed by a melt-
curve analysis. Each primer pair detected the full range
of standards with a correlation of R2 > 0.99.
Reviewers’ comments
Review by Rory Johnson (Centre de Regulacio Genomica,
nominated by Fyodor Kondrashov)
The authors report a new transcript resulting from a
fusion of two genes on distinct chromosomes. The range
of computational and experimental evidence support the
notion that this transcript results from a trans-splicing
event rather than from chromosomal translocation or
technical artifacts. The manuscript is clear and well pre-
sented. I do not have any technical or theoretical argu-
ments with this work. I only have one suggestion: If the
fusion transcript has any biological function/phenotype,
one might expect that it carries functional domains from
its two constituent genes. Therefore, one might expect
the fusion junction to occur at linker regions of func-
tional domains, and not interrupting the amino acid
sequence in the middle of such a domain. Therefore, I
would suggest that the authors comment on where the
fusion occurs for both the protein coding sequences with
respect to their predicted functional domains, AND
include a diagram of the predicted domain structure of
the protein encoded by the fusion transcript. E.g. does
the fusion carry the zinc finger domain of ZC3HAV1L?
What is known about the functions of the two parent
protein coding genes?
Author’s response: We did not find any domain anno-
tation for ZC3HAV1L or CHMP1A in Pfam. Despite its
name, ZC3HAV1L is actually not a zinc-finger protein.
Therefore we did not pursue further the functional pre-
dictions of the putative fusion protein. In the revised
manuscript we included a comment on this subject.
Review by Gal Avital and Itai Yanai, Department of
Biology, Technion - Israel Institute of Technology
In this report, Fang et al. report a transcript that appears
to be trans-spliced between RNAs originating from two
different human chromosomes. Four paired-end reads
alone appear to support the chimeral transcript in the
examined ENCODE RNA-Seq data for one cell type
(HMEC). The PCR analysis implicates other cell types,
however, do any of these have RNA-Seq datasets in
ENCODE to further support this? The article mentions
two possible avenues for function following from such a
chimera: 1. a protein, and 2. an RNA that might serve to
proximally position chromosomes. While the transcript
has some of the hallmarks of real transcripts such as the
existence of splice variants and an exon-exon boundary,
the low expression level does little to support a functional
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putative protein? This can be checked by matching with
PFAM. For the second option, structural analysis can be
used to query for a stable fold. Overall, while the authors
have clearly gone to lengths to detect the chimera in vari-
ous tissues, a possible function would require additional
evidence.
Author’s response: We further analyzed 40 and 20 mil-
lion paired-end RNA-seq reads for normal lung and pla-
centa from ENCODE data, respectively, but did not find
evidence of the ZC3HAV1L-CHMP1A RNA fusion. Our
quantitative RT-PCR analysis suggests that levels of the
RNA fusion in HMEC are higher than in most other tis-
sues except for prostate, but we have not found appro-
priate RNA-seq data from normal prostate tissue to use
in computational analysis.
We agree that the low level of the chimeric transcript
suggests that it more likely has a non-coding function,
that could potentially influence genomic rearrangement.
We still leave open the possibility of protein-coding
function, since the fusion RNA indeed preserves an open
reading frame. As we indicated in response to the first
review, there is no domain annotation or relevant struc-
tural study for these two partner proteins, and therefore
we do not further characterize the putative fusion
protein at this time.
Additional file
Additional file 1: Alignment of the major and minor chimeric
transcripts detected in RT-PCR analyses. The predicted chimeric RNA
sequence is indicated in the top row, with annotations of exons below it.
Fusion coding sequences (CDS) and the exon3- variant (variant i) are
from nested PCR analysis of HMLE cDNA. Variants ii and iii are from PCR
analysis of HMLE cDNA, across ZC3HAV1L exon 2 and CHMP1A exon 6,
with partial introns indicated below. Variant iv is from PCR analysis of
human prostate cDNA, across ZC3HAV1L exon 2 and CHMP1A exon 6.
The annotations are based on [Genbank: NC_000007 REGION:
complement (138710452..138720775) GPC_000000031, NM_080660.3,
NM_001083314.2].
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ZC3HAV1L: Zinc finger CCCH-type antiviral 1-like; CHMP1A: Charged
multivesicular body protein 1A; HMEC: Human mammary epithelial cell;
HEK293T: Human embryonic kidney 293 T; qPCR: Quantitative PCR;
gDNA: Genomic DNA.
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